;PMID: 1515242
;source_file_2868.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..37] = [t:0..37]
;1)section:[e:43..54] = [t:43..54]
;2)section:[e:60..95] = [t:60..95]
;3)sentence:[e:99..259] = [t:99..259]
;4)section:[e:263..304] = [t:263..304]
;5)section:[e:308..392] = [t:308..392]
;6)sentence:[e:396..603] = [t:396..603]
;7)sentence:[e:604..799] = [t:604..799]
;8)sentence:[e:800..865] = [t:800..865]
;9)sentence:[e:866..904] = [t:866..904]
;10)sentence:[e:905..1018] = [t:905..1018]
;11)sentence:[e:1019..1111] = [t:1019..1111]
;12)sentence:[e:1112..1215] = [t:1112..1215]
;13)sentence:[e:1216..1335] = [t:1216..1335]
;14)section:[e:1339..1383] = [t:1339..1383]

;section 0 Span:0..37
;Eur J Cancer.  1992;28A(8-9):1319-23.
(SEC
  (FRAG (NNP:[0..3] Eur) (NNP:[4..5] J) (NNP:[6..12] Cancer) (.:[12..13] .)
        (CD:[15..19] 1992) (CC:[19..24] ;28A-LRB-) (CD:[24..26] 8-)
        (CD:[26..27] 9) (-RRB-:[27..28] -RRB-) (::[28..29] :) (CD:[29..33] 1319)
        (::[33..34] -) (CD:[34..36] 23) (.:[36..37] .)))

;section 1 Span:43..54
;Comment in:
(SEC
  (FRAG (NNP:[43..50] Comment) (IN:[51..53] in) (NNP:[53..54] :)))

;section 2 Span:60..95
;Eur J Cancer. 1992;28A(8-9):1301-2.
(SEC
  (FRAG (NNP:[60..63] Eur) (NNP:[64..65] J) (NNP:[66..72] Cancer) (.:[72..73] .)
        (CD:[74..78] 1992) (CC:[78..83] ;28A-LRB-) (CD:[83..85] 8-)
        (CD:[85..86] 9) (-RRB-:[86..87] -RRB-) (::[87..88] :)
        (CD:[88..95] 1301-2.)))

;sentence 3 Span:99..259
;Toxicity of single-day high-dose vincristine, melphalan, etoposide and 
;carboplatin consolidation with autologous bone marrow rescue in advanced 
;neuroblastoma.
;[235..243]:malignancy-clinical-stage:"advanced"
;[245..258]:malignancy-type:"neuroblastoma"
(SENT
  (NP-HLN
    (NP (NN:[99..107] Toxicity))
    (PP (IN:[108..110] of)
      (NP
        (NP
          (NML (JJ:[111..117] single) (HYPH:[117..118] -) (NN:[118..121] day))
          (NML (JJ:[122..126] high) (HYPH:[126..127] -) (NN:[127..131] dose)))
        (NML (NN:[132..143] vincristine) (,:[143..144] ,)
             (NN:[145..154] melphalan) (,:[154..155] ,)
             (NN:[156..165] etoposide) (CC:[166..169] and)
             (NN:[171..182] carboplatin))
        (NN:[183..196] consolidation)))
    (PP (IN:[197..201] with)
      (NP (JJ:[202..212] autologous)
        (NML (NN:[213..217] bone) (NN:[218..224] marrow))
        (NN:[225..231] rescue)))
    (PP (IN:[232..234] in)
      (NP (VBN:[235..243] advanced) (NN:[245..258] neuroblastoma)))
    (.:[258..259] .)))

;section 4 Span:263..304
;Gordon SJ, Pearson AD, Reid MM, Craft AW.
(SEC
  (FRAG (NNP:[263..269] Gordon) (NNP:[270..272] SJ) (,:[272..273] ,)
        (NNP:[274..281] Pearson) (NNP:[282..284] AD) (,:[284..285] ,)
        (NNP:[286..290] Reid) (NNP:[291..293] MM) (,:[293..294] ,)
        (NNP:[295..300] Craft) (NNP:[301..303] AW) (.:[303..304] .)))

;section 5 Span:308..392
;Department of Child Health, Medical School, University of Newcastle upon
;Tyne,  U.K.
(SEC
  (FRAG (NNP:[308..318] Department) (IN:[319..321] of) (NNP:[322..327] Child)
        (NNP:[328..334] Health) (,:[334..335] ,) (NNP:[336..343] Medical)
        (NNP:[344..350] School) (,:[350..351] ,) (NNP:[352..362] University)
        (IN:[363..365] of) (NNP:[366..375] Newcastle) (IN:[376..380] upon)
        (NNP:[381..385] Tyne) (,:[385..386] ,) (NNP:[388..392] U.K.)))

;sentence 6 Span:396..603
;16 unselected patients with advanced neuroblastoma were given high-dose 
;consolidation chemotherapy with vincristine, melphalan, etoposide and 
;carboplatin over 5 h followed by autologous bone marrow rescue.
;[424..432]:malignancy-clinical-stage:"advanced"
;[433..446]:malignancy-type:"neuroblastoma"
(SENT
  (S
    (NP-SBJ-1
      (NP (CD:[396..398] 16) (JJ:[399..409] unselected)
          (NNS:[410..418] patients))
      (PP (IN:[419..423] with)
        (NP (VBN:[424..432] advanced) (NN:[433..446] neuroblastoma))))
    (VP (VBD:[447..451] were)
      (VP (VBN:[452..457] given)
        (NP-1 (-NONE-:[457..457] *))
        (NP
          (NP
            (NML (JJ:[458..462] high) (HYPH:[462..463] -) (NN:[463..467] dose))
            (NN:[469..482] consolidation) (NN:[483..495] chemotherapy))
          (PP (IN:[496..500] with)
            (NP (NN:[501..512] vincristine) (,:[512..513] ,)
                (NN:[514..523] melphalan) (,:[523..524] ,)
                (NN:[525..534] etoposide) (CC:[535..538] and)
                (NN:[540..551] carboplatin))))
        (PP-TMP (IN:[552..556] over)
          (NP (CD:[557..558] 5) (NN:[559..560] h)))
        (S-ADV
          (NP-SBJ (-NONE-:[560..560] *))
          (VP (VBN:[561..569] followed)
            (NP (-NONE-:[569..569] *))
            (PP (IN:[570..572] by)
              (NP-LGS (JJ:[573..583] autologous)
                (NML (NN:[584..588] bone) (NN:[589..595] marrow))
                (NN:[596..602] rescue)))))))
    (.:[602..603] .)))

;sentence 7 Span:604..799
;3 patients died  from treatment-related toxicity, 2 from disease, 1 is alive
;with disease and 10  are alive and disease-free a median of 12.5 months
;(range 2-38 months) after  bone marrow rescue.
(SENT
  (S
    (S
      (NP-SBJ=1 (CD:[604..605] 3) (NNS:[606..614] patients))
      (VP (VBD:[615..619] died)
        (PP=2 (IN:[621..625] from)
          (NP
            (ADJP (NN:[626..635] treatment) (HYPH:[635..636] -)
                  (VBN:[636..643] related))
            (NN:[644..652] toxicity)))))
    (,:[652..653] ,)
    (S
      (NP-SBJ=1 (CD:[654..655] 2))
      (PP=2 (IN:[656..660] from)
        (NP (NN:[661..668] disease))))
    (,:[668..669] ,)
    (S
      (NP-SBJ (CD:[670..671] 1))
      (VP (VBZ:[672..674] is)
        (ADJP-PRD (JJ:[675..680] alive)
          (PP (IN:[681..685] with)
            (NP (NN:[686..693] disease))))))
    (CC:[694..697] and)
    (S
      (NP-SBJ (CD:[698..700] 10))
      (VP (VBP:[702..705] are)
        (ADJP-PRD
          (ADJP (JJ:[706..711] alive))
          (CC:[712..715] and)
          (ADJP (NN:[716..723] disease) (HYPH:[723..724] -) (JJ:[724..728] free)))
        (NP-ADV
          (NP (DT:[729..730] a) (NN:[731..737] median))
          (PP (IN:[738..740] of)
            (NP
              (NP (CD:[741..745] 12.5) (NNS:[746..752] months)
                (PRN (-LRB-:[753..754] -LRB-)
                  (S
                    (NP-SBJ (NN:[754..759] range))
                    (NP-PRD
                      (QP (CD:[760..761] 2) (HYPH:[761..762] -)
                          (CD:[762..764] 38))
                      (NNS:[765..771] months)))
                  (-RRB-:[771..772] -RRB-)))
              (PP-TMP (IN:[773..778] after)
                (NP
                  (NML (NN:[780..784] bone) (NN:[785..791] marrow))
                  (NN:[792..798] rescue))))))))
    (.:[798..799] .)))

;sentence 8 Span:800..865
;All had bone marrow toxicity, most mucositis and 6 had  seizures.
(SENT
  (S
    (S
      (NP-SBJ=1 (DT:[800..803] All))
      (VP (VBD:[804..807] had)
        (NP=2
          (NML (NN:[808..812] bone) (NN:[813..819] marrow))
          (NN:[820..828] toxicity))))
    (,:[828..829] ,)
    (S
      (NP-SBJ=1 (JJS:[830..834] most))
      (NP=2 (NN:[835..844] mucositis)))
    (CC:[845..848] and)
    (S
      (NP-SBJ (CD:[849..850] 6))
      (VP (VBD:[851..854] had)
        (NP (NNS:[856..864] seizures))))
    (.:[864..865] .)))

;sentence 9 Span:866..904
;Renal failure was unexpectedly severe.
(SENT
  (S
    (NP-SBJ (JJ:[866..871] Renal) (NN:[872..879] failure))
    (VP (VBD:[880..883] was)
      (ADJP-PRD (RB:[884..896] unexpectedly) (JJ:[897..903] severe)))
    (.:[903..904] .)))

;sentence 10 Span:905..1018
;In the last 3 patients,  administration of carboplatin was delayed by 18 h in
;an attempt to reduce renal  damage.
(SENT
  (S
    (PP-LOC (IN:[905..907] In)
      (NP (DT:[908..911] the) (JJ:[912..916] last) (CD:[917..918] 3)
          (NNS:[919..927] patients)))
    (,:[927..928] ,)
    (NP-SBJ-1
      (NP (NN:[930..944] administration))
      (PP (IN:[945..947] of)
        (NP (NN:[948..959] carboplatin))))
    (VP (VBD:[960..963] was)
      (VP (VBN:[964..971] delayed)
        (NP-1 (-NONE-:[971..971] *))
        (PP-TMP (IN:[972..974] by)
          (NP (CD:[975..977] 18) (NN:[978..979] h)))
        (PP (IN:[980..982] in)
          (NP (DT:[983..985] an) (NN:[986..993] attempt)
            (S
              (NP-SBJ (-NONE-:[993..993] *))
              (VP (TO:[994..996] to)
                (VP (VB:[997..1003] reduce)
                  (NP (JJ:[1004..1009] renal) (NN:[1011..1017] damage)))))))))
    (.:[1017..1018] .)))

;sentence 11 Span:1019..1111
;The results show that this regimen produces significant morbidity and  has a
;high mortality.
(SENT
  (S
    (NP-SBJ (DT:[1019..1022] The) (NNS:[1023..1030] results))
    (VP (VBP:[1031..1035] show)
      (SBAR (IN:[1036..1040] that)
        (S
          (NP-SBJ (DT:[1041..1045] this) (NN:[1046..1053] regimen))
          (VP
            (VP (VBZ:[1054..1062] produces)
              (NP (JJ:[1063..1074] significant) (NN:[1075..1084] morbidity)))
            (CC:[1085..1088] and)
            (VP (VBZ:[1090..1093] has)
              (NP (DT:[1094..1095] a) (JJ:[1096..1100] high)
                  (NN:[1101..1110] mortality)))))))
    (.:[1110..1111] .)))

;sentence 12 Span:1112..1215
;Although the overall outcome is encouraging, too few  patients have been
;studied to gauge its efficacy.
(SENT
  (S
    (SBAR-ADV (IN:[1112..1120] Although)
      (S
        (NP-SBJ (DT:[1121..1124] the) (JJ:[1125..1132] overall)
                (NN:[1133..1140] outcome))
        (VP (VBZ:[1141..1143] is)
          (ADJP-PRD (VBG:[1144..1155] encouraging)))))
    (,:[1155..1156] ,)
    (NP-SBJ-1
      (NP (RB:[1157..1160] too) (JJ:[1161..1164] few)
          (NNS:[1166..1174] patients))
      (S-2 (-NONE-:[1174..1174] *ICH*)))
    (VP (VBP:[1175..1179] have)
      (VP (VBN:[1180..1184] been)
        (VP (VBN:[1185..1192] studied)
          (NP-1 (-NONE-:[1192..1192] *))
          (S-2
            (NP-SBJ (-NONE-:[1192..1192] *))
            (VP (TO:[1193..1195] to)
              (VP (VB:[1196..1201] gauge)
                (NP (PRP$:[1202..1205] its) (NN:[1206..1214] efficacy))))))))
    (.:[1214..1215] .)))

;sentence 13 Span:1216..1335
;Whether such aggressive  consolidation is necessary in heavily pretreated
;children with neuroblastoma  remains unknown.
;[1290..1298]:malignancy-developmental-state:"children"
;[1304..1317]:malignancy-type:"neuroblastoma"
(SENT
  (S
    (SBAR-SBJ (IN:[1216..1223] Whether)
      (S
        (NP-SBJ (JJ:[1224..1228] such) (JJ:[1229..1239] aggressive)
                (NN:[1241..1254] consolidation))
        (VP (VBZ:[1255..1257] is)
          (ADJP-PRD (JJ:[1258..1267] necessary))
          (PP-LOC (IN:[1268..1270] in)
            (NP
              (NP
                (ADJP (RB:[1271..1278] heavily) (VBN:[1279..1289] pretreated))
                (NNS:[1290..1298] children))
              (PP (IN:[1299..1303] with)
                (NP (NN:[1304..1317] neuroblastoma))))))))
    (VP (VBZ:[1319..1326] remains)
      (ADJP-PRD (JJ:[1327..1334] unknown)))
    (.:[1334..1335] .)))

;section 14 Span:1339..1383
;PMID: 1515242 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1339..1343] PMID) (::[1343..1344] :) (CD:[1345..1352] 1515242)
        (NN:[1353..1354] -LSB-) (NNP:[1354..1360] PubMed) (::[1361..1362] -)
        (NN:[1363..1370] indexed) (IN:[1371..1374] for)
        (NNP:[1375..1383] MEDLINE-RSB-)))
